ストックスクリーナーアプリを入手
1,183.46
0.13%
1.57
アフターアワーズ：
1183.56
0.10
+0.01%
前日終値:
$1,181.89
開ける：
$1185.32
24時間の取引高:
1.91M
Relative Volume:
0.73
時価総額：
$1.05T
収益：
$72.25B
当期純損益:
$25.28B
株価収益率:
42.60
EPS:
27.781
ネットキャッシュフロー:
$10.37B
1週間 パフォーマンス:
+2.65%
1か月 パフォーマンス:
-4.07%
6か月 パフォーマンス:
+29.15%
1年 パフォーマンス:
+65.61%
1日の値動き範囲:
$1,160.84
$1,190.00
1週間の範囲:
$1,134.41
$1,197.79
52週間の値動き範囲:
$716.08
$1,292.65
Lilly Eli Co Stock (LLY) Company Profile
Compare LLY vs JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,183.46 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
271.22 | 652.31B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
264.34 | 468.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.78 | 365.09B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
145.46 | 272.89B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-12-16 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 繰り返されました | BofA Securities | Buy |
| 2025-12-15 | 繰り返されました | Goldman | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-10 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 繰り返されました | BMO Capital Markets | Outperform |
| 2025-10-14 | アップグレード | Erste Group | Hold → Buy |
| 2025-09-17 | ダウングレード | Berenberg | Buy → Hold |
| 2025-08-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2025-08-18 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | ダウングレード | Erste Group | Buy → Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-09-13 | 再開されました | Citigroup | Buy |
| 2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
| 2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
| 2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-20 | 再開されました | UBS | Buy |
| 2023-08-09 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-26 | 繰り返されました | Citigroup | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-24 | 繰り返されました | BofA Securities | Buy |
| 2023-05-24 | 繰り返されました | UBS | Buy |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-09-22 | アップグレード | UBS | Neutral → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-03-10 | 開始されました | Daiwa Securities | Outperform |
| 2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-16 | 繰り返されました | BofA Securities | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-21 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
| 2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-03-12 | 開始されました | JP Morgan | Overweight |
| 2019-01-23 | 開始されました | UBS | Buy |
| 2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-10-01 | 繰り返されました | SunTrust | Buy |
| 2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
Eli Lilly (LLY) Gains FDA Nod for Olumiant in Pediatric Alopecia Areata - gurufocus.com
Eli Lilly stock closes at USD 1,181.89, up 2.68 percent at the closing bell - AD HOC NEWS
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says - Reuters
Eli Lilly gives a helping hand to Kenosha-area food pantries - Journal Times
Lilly wins approval for once-weekly insulin shot - STAT
Lilly ordered to pay Nektar $90M in damages over rezpeg dispute - FirstWord
Why Is Eli Lilly (NYSE:LLY) Drawing Fresh NYSE Attention? - Kalkine Media
Jury awards Nektar Therapeutics $90M in rezpeg dispute with Eli Lilly - Dealroom
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury FundsEli Lilly (NYS - Benzinga
Eli Lilly stock gains 2.86 percent as guidance rises - AD HOC NEWS
Editorial: Lilly CEO calls on city, state to get serious about quality of life - Indianapolis Business Journal
Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly - Investing.com Canada
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? - The Motley Fool
FDA approves Lilly’s Onswik for type 2 diabetes in adults - yahoo.com
91-year-old investor sees healthcare titan doubling in 3 years - thestreet.com
Eli Lilly and Co. stock gains 3.51 percent ahead of the open - AD HOC NEWS
Jurisdictional Skepticism Puts Eli Lilly Appeal On Thin Ice - Law360
RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
Eli Lilly Hit With $90M Verdict In Nektar's Rezpeg Breach Suit - Law360
Eli Lilly (LLY) Stock Is Up, What You Need To Know - Yahoo Finance Australia
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? - The Motley Fool
Eli Lilly & Co. stock outperforms competitors on strong trading day - MarketWatch
Medicare just handed Eli Lilly a massive weight-loss win - sg.finance.yahoo.com
Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact - MedCity News
FDA approves Eli Lilly's once-weekly insulin On... - Pluang
Eli Lilly and InnoCare sign drug discovery deal worth up to $3.35B - qz.com
Eli Lilly and Company (NYSE:LLY) Anchors Healthcare Focus on Deals and Clearances - Kalkine Media
Lilly Wins FDA Nod For Weekly Insulin, Signs $3.25 Billion InnoCare Pact - Benzinga
Lilly’s Ricks says state needs to emphasize quality of life, health care - dailyjournal.net
Lilly extends China innovation push in $3.35B Innocare deal - BioWorld News
FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes - Dealroom
InnoCare and Lilly ink deal worth up to $3.35 billion across five drug targets - The Pharma Letter
US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes - Reuters
Eli Lilly Rises After FDA Approval for Once-Weekly Diabetes Insulin - Quiver Quantitative
How Is Lilly (NYSE:LLY) Broadening Its S&P 500 Pipeline Today? - Kalkine Media
Healthcare is a great defensive sector to be in when the rest of the market is crapping in their pants! - Moomoo
Eli Lilly and Co Stock (LLY) Moved Up by 3.73% on Sep 24: A Full Analysis - TradingKey
InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly - Pharmaceutical Executive
Eli Lilly Stock Price Today (LLY) | NYSE - TechGraph
Governor Abbott Delivers Remarks At Lilly Groundbreaking In Houston - Texas Border Business
Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare - pharmaceutical-technology.com
LLY Looks 26.0% Undervalued on GF Value™ After FDA Approval of O - GuruFocus
Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal - pmlive.com
LLY Looks 26.0% Undervalued on GF Value™ After FDA Approval of W - GuruFocus
Eli Lilly signs deal worth up to USD 3.35bn with China's InnoCare - medwatch.com
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes - Eli Lilly
Lilly's FDA-approved weekly insulin could mean over 300 fewer shots a year than daily insulin - Stock Titan
InnoCare and Eli Lilly strike research collaboration worth up to $3.35B - Dealroom
InnoCare Pharma partners with Eli Lilly in drug research deal - chinadaily.com.cn
InnoCare Pharma Partners with Eli Lilly on New Drug Development, Potential Milestones Up to $3.25 Billion - finance.biggo.com
Lilly reaches $3.35B deal with China's InnoCare - Breakingthenews.net
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
0.20%
0.29%
大文字化:
|
ボリューム (24 時間):